Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yuki Tsuji

Showing results (41-50 of 103) with videos related to

Pageof 11
Sort By:
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|May 6, 2022
Rifaximin and lubiprostone mitigate liver fibrosis development by repairing gut barrier function in diet-induced rat steatohepatitisMasahide Enomoto, Kosuke Kaji, Norihisa Nishimura, et al.
Cells|September 29, 2019
TGR5 Activation Modulates an Inhibitory Effect on Liver Fibrosis Development Mediated by Anagliptin in Diabetic RatsDaisuke Kaya, Kosuke Kaji, Yuki Tsuji, et al.
World Journal of Gastroenterology|September 11, 2025
Dual therapy with vildagliptin and sacubitril/valsartan alleviates portal hypertension and inhibits soluble epoxide hydrolase in cirrhotic ratsMasafumi Oyama, Kosuke Kaji, Norihisa Nishimura, et al.
Biochimica Et Biophysica Acta. Molecular Cell Research|December 14, 2023
Blockade of angiotensin II modulates insulin-like growth factor 1-mediated skeletal muscle homeostasis in experimental steatohepatitisMisako Tanaka, Kosuke Kaji, Norihisa Nishimura, et al.
Biomedicines|May 27, 2023
A Combination of an Angiotensin II Receptor and a Neprilysin Inhibitor Attenuates Liver Fibrosis by Preventing Hepatic Stellate Cell ActivationJunya Suzuki, Kosuke Kaji, Norihisa Nishimura, et al.
Journal of Clinical Medicine|May 20, 2020
Increased Endotoxin Activity Is Associated with the Risk of Developing Acute-on-Chronic Liver FailureHiroaki Takaya, Tadashi Namisaki, Shinya Sato, et al.
Digestive Diseases (Basel, Switzerland)|October 28, 2019
Effectiveness of Lusutrombopag in Patients with Mild to Moderate ThrombocytopeniaYuki Tsuji, Hideto Kawaratani, Koji Ishida, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|April 17, 2019
Blocking development of liver fibrosis augments hepatic progenitor cell-derived liver regeneration in a mouse chronic liver injury modelMitsuteru Kitade, Kosuke Kaji, Norihisa Nishimura, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|June 20, 2020
Effect of three or more treatments with lusutrombopag in patients with cirrhotic thrombocytopenia: A retrospective single-center studyHideto Kawaratani, Yuki Tsuji, Koji Ishida, et al.
Journal of Cardiovascular Pharmacology and Therapeutics|March 30, 2013
Comparison of bumetanide- and metolazone-based diuretic regimens to furosemide in acute heart failureTien M H Ng, Erica Konopka, Alifiya F Hyderi, et al.
Pageof 11

Showing results (41-50 of 103) with videos related to

Sort By:
Pageof 11
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|May 6, 2022
Rifaximin and lubiprostone mitigate liver fibrosis development by repairing gut barrier function in diet-induced rat steatohepatitisMasahide Enomoto, Kosuke Kaji, Norihisa Nishimura, et al.
Cells|September 29, 2019
TGR5 Activation Modulates an Inhibitory Effect on Liver Fibrosis Development Mediated by Anagliptin in Diabetic RatsDaisuke Kaya, Kosuke Kaji, Yuki Tsuji, et al.
World Journal of Gastroenterology|September 11, 2025
Dual therapy with vildagliptin and sacubitril/valsartan alleviates portal hypertension and inhibits soluble epoxide hydrolase in cirrhotic ratsMasafumi Oyama, Kosuke Kaji, Norihisa Nishimura, et al.
Biochimica Et Biophysica Acta. Molecular Cell Research|December 14, 2023
Blockade of angiotensin II modulates insulin-like growth factor 1-mediated skeletal muscle homeostasis in experimental steatohepatitisMisako Tanaka, Kosuke Kaji, Norihisa Nishimura, et al.
Biomedicines|May 27, 2023
A Combination of an Angiotensin II Receptor and a Neprilysin Inhibitor Attenuates Liver Fibrosis by Preventing Hepatic Stellate Cell ActivationJunya Suzuki, Kosuke Kaji, Norihisa Nishimura, et al.
Journal of Clinical Medicine|May 20, 2020
Increased Endotoxin Activity Is Associated with the Risk of Developing Acute-on-Chronic Liver FailureHiroaki Takaya, Tadashi Namisaki, Shinya Sato, et al.
Digestive Diseases (Basel, Switzerland)|October 28, 2019
Effectiveness of Lusutrombopag in Patients with Mild to Moderate ThrombocytopeniaYuki Tsuji, Hideto Kawaratani, Koji Ishida, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|April 17, 2019
Blocking development of liver fibrosis augments hepatic progenitor cell-derived liver regeneration in a mouse chronic liver injury modelMitsuteru Kitade, Kosuke Kaji, Norihisa Nishimura, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|June 20, 2020
Effect of three or more treatments with lusutrombopag in patients with cirrhotic thrombocytopenia: A retrospective single-center studyHideto Kawaratani, Yuki Tsuji, Koji Ishida, et al.
Journal of Cardiovascular Pharmacology and Therapeutics|March 30, 2013
Comparison of bumetanide- and metolazone-based diuretic regimens to furosemide in acute heart failureTien M H Ng, Erica Konopka, Alifiya F Hyderi, et al.
Pageof 11